Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis

Infection

Volumn 37, Issue 5, 2009, Pages 418-423

  Riethmueller, J ^a   Junge, S ^b   Schroeter, T W ^c   Kuemmerer, K ^d   Franke, P ^a   Ballmann, M ^b   Claass, A ^c   Broemme, S ^e   Jeschke, R ^f   Hebestreit, A ^f   Staab, D ^g   Koetz, K ^g   Doering, G ^h   Stern, M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g Bereich Behring   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTAZIDIME; COLISTIN; IMMUNOGLOBULIN G; MEROPENEM; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HUMAN; LEUKOCYTE COUNT; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350159342     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-8116-5     Document Type: Article

References (22)

1. C. Schaedel I. de Monestrol L. Hjelte M. Johannesson R. Kornfalt A. Lindblad B. Strandvik L. Wahlgren L. Holmberg 2002 Predictors of deterioration of lung function in cystic fibrosis Pediatr Pulmonol 33 483 491 10.1002/ppul.10100 1:STN:280:DC%2BD383oslOgug%3D%3D 12001283 (Pubitemid 34547870)
2. M.H. Schoeni C. Casaulta-Aebischer 2000 Nutrition and lung function in cystic fibrosis patients: review Clin Nutr 19 79 85 10.1054/clnu.1999.0080 (Pubitemid 30316020)
3. G. Steinkamp B. Wiedemann 2002 Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project Thorax 57 596 601 10.1136/thorax.57.7.596 1:STN:280:DC%2BD38zltlWhuw%3D%3D 12096202 (Pubitemid 34761761)
4. G. Doering S.P. Conway H.G. Heijerman M.E. Hodson N. Hoiby A. Smyth D.J. Touw 2000 Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur Respir J 16 749 767 10.1034/j.1399-3003.2000.16d30.x (Pubitemid 30834538)
5. C.M. Kercsmar R.C. Stern M.D. Reed C.M. Myers D. Murdell J.L. Blumer 1983 Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response J Antimicrob Chemother 12 [Suppl A] 289 295 6352634
6. H. Permin C. Koch N. Hoiby H.O. Christensen A.F. Moller S. Moller 1983 Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis J Antimicrob Chemother 12 [Suppl A] 313 323 6352636
7. A.A. Vinks R.W. Brimicombe H.G. Heijerman W. Bakker 1997 Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics J Antimicrob Chemother 40 125 133 10.1093/jac/40.1.125 1:CAS:528:DyaK2sXltVCit78%3D 9249216 (Pubitemid 27341645)
8. I. Rappaz L.A. Decosterd J. Bille M. Pilet N. Belaz M. Roulet 2000 Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children Eur J Pediatr 159 919 925 10.1007/PL00008370 1:CAS:528:DC%2BD3cXotFWht70%3D 11131352
9. J. Riethmueller A. Busch V. Damm R. Ziebach M. Stern 2002 Home and hospital antibiotic treatment prove similarly effective in cystic fibrosis Infection 30 387 391 10.1007/s15010-002-2095-0 1:STN:280:DC%2BD38jhsFymug%3D%3D 12478330 (Pubitemid 35447470)
10. G. Doering H.J. Obernesser K. Botzenhart B. Flehmig N. Hoiby A. Hofmann 1983 Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis J Infect Dis 147 744 750
11. A. Bauernfeind R. Bertele K. Harms G. Hörl R. Jungwirth C. Petermueller B. Przyklenk C. Weisslein-Pfister 1987 Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis Infection 15 270 277 10.1007/BF01644137 1:STN:280:DyaL1c%2FjtFOnug%3D%3D 3117700
12. J.E. Hoppe U. Theurer-Mainka M. Stern 1995 Comparison of three methods for culturing throat swabs from cystic fibrosis patients J Clin Microbiol 33 1896 1898 1:STN:280:DyaK2MzpsFShtw%3D%3D 7665666
13. P.H. Quanjer 1983 Standardized lung function testing. Report Working Party "Standardization of Lung Function Tests", European Community for Coal and Steel Bull Eur Physiopathol Respir 19 1 95
14. Zapletal A, Samanek M, Paul T: Lung function in children and adolescents. Methods, reference values. Karger, Basel, 1987.
15. B. Salh D. Bilton M. Dodd J. Abbot K. Webb 1992 A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis Scand J Infect Dis 24 215 218 10.3109/00365549209052615 1:STN:280:DyaK38zltFSmtg%3D%3D 1641599
16. S. Cunningham J.R. McColm A. Mallinson I. Boyd 2003 Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis Pediatr Pulmonol 36 43 48 10.1002/ppul.10311 12772222 (Pubitemid 36734765)
17. J. Berkhout L.J. Visser P.J. van den Broek J.A. van de Klundert H. Mattie 2003 Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion Antimicrob Agents Chemother 47 1862 1866 10.1128/AAC.47.6.1862-1866.2003 1:CAS:528:DC%2BD3sXktlymtL0%3D 12760859 (Pubitemid 36637806)
18. B. Byl D. Baran F. Jacobs A. Herschuelz J.P. Thys 2001 Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients J Antimicrob Chemother 48 325 327 10.1093/jac/48.2.325 1:CAS:528: DC%2BD3MXmsVeitLw%3D 11481316
19. J. Kuzemko C. Crawford 1989 Continuous infusion of ceftazidime in cystic fibrosis Lancet 2 385 10.1016/S0140-6736(89)90561-8 1:STN:280: DyaL1MzktleltQ%3D%3D 2569571
20. A.A. Vinks J.W. Mouton D.J. Touw H.G. Heijerman M. Danhof W. Bakker 1996 Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy Antimicrob Agents Chemother 40 1091 1097 1:CAS:528:DyaK28XislClsb4%3D 8723446
21. A.A. Vinks H.G. Touw M. Heijerman G. Danhof P. de Leede W. Bakker 1994 Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home Ther Drug Monit 16 341 348 10.1097/00007691-199408000-00002 1:STN:280:DyaK2M%2FmsV2nuw%3D%3D 7974622
22. L. Alou L. Aguilar D. Sevillano M.-J. Gimenez O. Echeverria M.L. Gomez-Lus J. Prieto 2005 Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model J Antimicrob Chemother 55 209 213 10.1093/jac/dkh536 1:CAS:528:DC%2BD2MXovVyqtQ%3D%3D 15650000 (Pubitemid 40331147)